Cost-of-illness study of type 2 diabetes mellitus in Colombia

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 26, Issue 1, 2009, Pages 55-63

  González, Camilo J ^a   Walker, John H ^b   Einarson, Thomas R ^c  

^a Merck Sharp and Dohme   (Colombia)

^b BROCK UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Burden of illness; Colombia; Cost of illness; Diabetes mellitus; Latin America

Indexed keywords

DIABETES; DISEASE INCIDENCE; ECONOMIC ANALYSIS; ENDOCRINOLOGY; HEALTH CARE; HUMAN CAPITAL; LITERATURE REVIEW; MARKOV CHAIN; POPULATION STRUCTURE;

COLOMBIA; SOUTH AMERICA;

ARTICLE; COLOMBIA; COST OF ILLNESS; ECONOMICS; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS;

COLOMBIA; COST OF ILLNESS; DIABETES MELLITUS, TYPE 2; HUMANS;

EID: 70349132690     PISSN: 10204989     EISSN: 16805348     Source Type: Journal    
DOI: 10.1590/S1020-49892009000700009     Document Type: Article

References (47)

1. World Health Organization. Diabetes mellitus fact sheet no. 312. Geneva: WHO; 2006.
2. Sobel BE, Schneider DJ. Cardiovascular complications in diabetes mellitus. Curr Opin Pharmacol. 2005;5:143-148
3. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134-1146
4. Wannamethee SG, Shaper AG, Lennon L. Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease. Heart. 2004;90:1398-1403
5. Ettaro L, Songer TJ, Zhang P, Engelgau MM. Cost-of-illness studies in diabetes mellitus. Pharmacoeconomics. 2004;22:149-164
6. Akobundu E, Ju J, Blatt L, Mullins CD. Cost-of-illness studies: a review of current methods. Pharmacoeconomics. 2006;24:869-890
7. Oliva J, Lobo F, Molina B, Monereo S. Direct health care costs of diabetic patients in Spain Diabetes Care. 2004;27:2616-2621
8. Taylor AK. Medical expenditures and insurance coverage for people with diabetes: estimates from the National Medical Care Expenditure Survey. Diabetes Care. 1987;10:87-94.
9. Massi-Bennedetti M, CODE-2 Advisory Board. The cost of diabetes type II in Europe, the CODE-2 Study. Diabetologia. 2002;45:S1-4.
10. Mata M, Antoñanzas F, Tafalla M, Sanz P. El coste de la diabetes tipo 2 en España. El estudio CODE-2. Gac Sanit. 2002;16:511-520
11. Hart WM, Espinosa C, Rovira J. A simulation model of the cost of the incidence of IDDM in Spain. Diabetologia. 1997;40:311-318
12. Stern Z, Levy R. The direct cost of type 1 diabetes mellitus in Israel. Diabet Med. 1994;11: 528-533
13. Aschner P. Diabetes trends in Latin America. Diabetes Metab Res Rev. 2002;18(Suppl 3): S27-31.
14. American Diabetes Association. Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care. 1998;21:296-309.
15. Barceló A, Aedo C, Rajpathak S, Robles S. The cost of diabetes in Latin America and the Caribbean. Bull World Health Organ. 2003; 81(1):19-27.
16. International Diabetes Federation. Clinical Guidelines Task Force Global. Guideline for type 2 diabetes. Brussels: IDF; 2005.
17. Barceló A, Rajpathak S. Incidence and prevalence of diabetes mellitus in the Americas. Pan Am J Public Health. 2001;10:300-308
18. World Health Organization. WHO statistical information system (WHOSIS). Life tables for WHO member states, Colombia 2004. Available from: http://www3.who.int/whosis/life/life-tables/life-tables-process.cfm? country=col&language=en#. Accessed 3 April 2007.
19. Clarke PM, Gray AM, Briggs A, Farmer AJ,Fenn P, Stevens RJ, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47: 1747-1759
20. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853
21. O'Reilly D, Hopkins R, Blackhouse G, Clarke P, Hux J, Guan J, et al. Development of an Ontario diabetes economic model (ODEM) and application to a multidisciplinary primary care diabetes management program. Toronto: Ontario Ministry of Health and Long-Term Care; 2006.
22. Lamotte M, Annemans L, Lefever A, Nechelput M, Masure J. A health economic model to assess the long-term effects and cost- effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care. 2002;25:303-308
23. United States Renal Data System. The 2006 annual data report graphics as Microsoft PowerPointtm color slides. Available from: http://www.usrds.org/ slides.htm. Accessed 4 April 2007.
24. Zhou H, Isaman DJ, Messinger S, Brown MB, Klein R, Brandle M, et al. A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care. 2005;28:2856-2863
25. World Health Organization. Purchase power parity, choosing interventions that are cost effective (WHO-CHOICE). Available from: http://www.who.int/choice/ costs/ppp/ en/index.html. Accessed 4 April 2007.
26. Banco de la República. Reportes de inflación en Colombia, informes sobre inflación. Bogotá: Banco de la Republica; 2005. Available from: http://www.banrep.gov.co/. Accessed 4 April 2007.
27. Banco de la República. Reportes de inflación en Colombia, informes sobre inflación. Bogotá: Banco de la Republica; 2006. Available from: http://www.banrep.gov.co/. Accessed 4 April 2007.
28. Banco de la República. Reportes de inflación en Colombia, informes sobre inflación. Bogotá: Banco de la Republica; 2007. Available from: http://www.banrep.gov.co/. Accessed 4 April 2007.
29. Ministerio de Proteccion Social. Lista de precios de medicamentos y procedimientos qui- rurgicos y hospitalarios. Decreto 2423 of 2005. Bogota: Diario Oficial; 2005.
30. Farmaprecios. Guía de precios sugeridos al público, promedio de y para farmacias dependientes. 93rd ed. Bogota: Thomson PLM, S.A.; 2007.
31. Instituto Nacional de Cancerología Subdirec- ción de Investigaciones, Vigilancia Epidemiológica y Registro. Costos unitarios de la atención médica del infarto agudo del miocardio, cáncer de pulmón y epoc atribuibles al consumo de tabaco en Colombia, Instituto Nacional de Cancerológica y PAHO. Bogota: Instituto Nacional de Cancerología Subdirección de Investigaciones, Vigilancia Epidemiológica y Registro; 2006. Pp. 15-17.
32. Oliva J, Lobo F, Molina B, Monereo S. Estudios de los costes directos sanitarios de los pacientes con diabetes mellitus en España. Working papers 04-103 Economic series 01. Madrid: Universidad Carlos III de Madrid; 2004.
33. Arós F, Loma-Osorio A, Alonso A, Alonso JJ, Cabadés A, Coma-Canella I, et al. Guías de actuación clínica de la Sociedad Española de Cardiología en el infarto agudo de miocardio. Rev Esp Cardiol. 1999;52:919-956
34. Antoñanzas F, Anton F, Echevarria I, Juarez C. Clínica y epidemiologia de la insuficiencia cardiaca congestiva (ICC): un análisis de costes. Clín Cardiovasc. 1998;16:27-34.
35. Lamas J, Alonso M, Saavedra J, Garcia-Trio G, Rionda M, Ameijeiras M. Costes de la diálisis crónica en un hospital público: mitos y realidades. Nefrologia. 2001;21:283-294
36. Instituto del Seguro Social. Lista de precios de prestación servicios de salud del Instituto del Seguro Social. Acuerdo 312 de 2004. Bogota: Diario Oficial; 2004.
37. Chicaíza L. Fallas del mercado de la salud en Colombia: el caso de la insuficiencia renal crónica. Rev Econ Inst. 2005;7(12):191-208.
38. Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, de Alvaro F, et al. Coste-efectividad de irbesartan en pacientes hipertensos con nefropatía diabética tipo II: una perspectiva Española. Nefrología. 2004;23:231-238
39. Ray JA, Valentine WJ, Secnik K, Oglesby AK, Cordony A, Gordois A, et al. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Curr Med Res Opin. 2005;10:1617-1629
40. Mattke S, Balkrishnan A, Bergamo G, New- berry SJ. A review of methods to measure health-related productivity loss. Am J Manag Care. 2007;13:211-217
41. Mayfield J, Deb P, Whitecotton L. Work disability and diabetes. Diabetes Care. 1999;22: 1105-1109
42. Von Korff M, Katon W, Lin EH, Simon G, Ciechanowski P, Ludman E, et al. Work disability among individuals with diabetes. Diabetes Care. 2005;28:1326-1332
43. United Nations Children's Fund. Colombia- statistics, basic indicators. New York: UNICEF; 2005. Available from: http://www.unicef.org/infobycountry/ colombia-statistics.html? q=printme. Accessed 16 April 2007.
44. Banco de la República. Tasa de cambio 23 Abril de 2007. Available from: http://www. banrep.gov.co/. Accessed 23 April 2007.
45. Departamento Nacional de Estadística DANE. Población compensada censo general 2005 contador de población. Bogota: DANE; 2007. Available from: http://www.dane.gov.co/reloj/reloj-animado.php. Accessed 21 April 2007.
46. Henriksson F, Jonsson B. Diabetes: the cost of illness in Sweden. J Intern Med. 1998;244:461-468
47. National Institutes of Health. Disease-specific estimates of direct and indirect costs of illness and NIH support. Bethesda: NIH; 1995.